In radiotherapy treatment of upper-abdominal cancer patients, can response assessment with functional single photon emission computed tomography (SPECT) imaging be used to reduce kidney toxicity and improve the radiotherapy?

Sir Charles Gairdner Hospital0 个研究点目标入组 35 人开始时间: 2009年5月21日最近更新: 2021年6月28日

适应症

试验速览

暂无简介。

•Patient has histologically/cytologically proven adenocarcinoma of the pancreas or upper-gastrointestinal (GI) tract. Metastatic disease status excluded on whole body computed tomography (CT) series.
•Locoregional staging of primary disease has been undertaken with dual phase (arterial and portal) spiral CT.
•Adequate bone marrow function: Haemoglobin (Hb)>10, White Blood Cells (WBC)>3.5 (Neutrophilis>1.5), Platelets >100
•Serum creatinine <150
•Patient has given written informed consent.
•Performance status is East Coast Oncology Group (ECOG) grade 0, 1 or 2

•Major co-morbid illnesses that, in the opinion of the investigator, would jeopardise the likely completion of the treatment program.
•Patients with significant loss of bodyweight (>15% weight loss since diagnosis).
•Treatment with any previous cytotoxic chemotherapy for the malignancy.
•Previous abdominal radiotherapy.

发起方